To include your compound in the COVID-19 Resource Center, submit it here.

Vimpat lacosamide regulatory update

FDA approved an sNDA for Vimpat lacosamide as monotherapy to treat partial-onset seizures in

Read the full 144 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE